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Introduction {#jah32176-sec-0005}
============

Patients admitted with an acute coronary syndrome (ACS) are at increased risk of subsequent cardiovascular events, especially those with type 2 diabetes mellitus,[1](#jah32176-bib-0001){ref-type="ref"}, [2](#jah32176-bib-0002){ref-type="ref"} who constitute ≈30% of all ACS patients.[3](#jah32176-bib-0003){ref-type="ref"} Determining the predictors of death, myocardial infarction (MI), heart failure (HF), and stroke among these patients is important as it assists in identifying the individuals at highest risk of these various outcomes. These individuals should be the focus of the most intensive secondary preventive strategies. In the same way, risk stratification may help motivate both patients and clinicians in secondary preventive efforts. Lastly, predictive models can be used to select the highest risk individuals for trials of new secondary preventive therapies.

B‐type natriuretic peptide (BNP) and N‐terminal prohormone B‐type natriuretic peptide (NT‐proBNP) levels are well established predictors of HF hospitalization and mortality in patients with HF.[4](#jah32176-bib-0004){ref-type="ref"}, [5](#jah32176-bib-0005){ref-type="ref"}, [6](#jah32176-bib-0006){ref-type="ref"}, [7](#jah32176-bib-0007){ref-type="ref"} However, as the incidences of outcomes differ between patients with HF[8](#jah32176-bib-0008){ref-type="ref"} and patients with a recent ACS[9](#jah32176-bib-0009){ref-type="ref"} in a stable phase, it is less established how natriuretic peptides are associated with cardiovascular outcomes, especially subsequent MI and stroke, in the latter population.[3](#jah32176-bib-0003){ref-type="ref"}, [10](#jah32176-bib-0010){ref-type="ref"}, [11](#jah32176-bib-0011){ref-type="ref"}, [12](#jah32176-bib-0012){ref-type="ref"}, [13](#jah32176-bib-0013){ref-type="ref"}, [14](#jah32176-bib-0014){ref-type="ref"} Concentrations of natriuretic peptides may be affected by both asymptomatic myocardial ischemia[15](#jah32176-bib-0015){ref-type="ref"}, [16](#jah32176-bib-0016){ref-type="ref"} and atrial fibrillation,[17](#jah32176-bib-0017){ref-type="ref"}, [18](#jah32176-bib-0018){ref-type="ref"} which could make BNP and NT‐proBNP relevant as predictors of MI and stroke. However, trials investigating patients at high risk of atherosclerotic events have found conflicting results regarding both the predictive ability of natriuretic peptides and cardiovascular outcomes---including MI and stroke---as well as the predictive strength of BNP versus NT‐proBNP.[19](#jah32176-bib-0019){ref-type="ref"}, [20](#jah32176-bib-0020){ref-type="ref"}, [21](#jah32176-bib-0021){ref-type="ref"}, [22](#jah32176-bib-0022){ref-type="ref"}

We wanted to expand knowledge of these natriuretic peptides as predictors of death, cardiovascular death, myocardial infarction, heart failure, and stroke in patients with a recent coronary event and type 2 diabetes mellitus enrolled in the Evaluation of Lixisenatide in Acute Coronary Syndrome trial (ELIXA, NCT01147250). Data from the ELIXA trial allowed us to compare the predictive strength of baseline BNP and NT‐proBNP in a high risk ACS patient cohort with type 2 diabetes mellitus. In addition, prospective ascertainment during a reasonable follow‐up period, and adjudication of a variety of cardiovascular events, ensured detailed and validated data for analyses.

Methods {#jah32176-sec-0006}
=======

The ELIXA trial (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial included 6068 patients with type 2 diabetes mellitus and an acute coronary event within 180 days from randomization (index event).[23](#jah32176-bib-0023){ref-type="ref"} The study was approved by the appropriate national and institutional regulatory and ethics boards, and all subjects gave informed consent. The objective of the ELIXA trial was to assess the safety and efficacy of lixisenatide, a glucagon‐like peptide‐1 receptor agonist, on cardiovascular morbidity and mortality. Details of the trial design and the demographic and clinical characteristics of the included patients have been reported previously.[24](#jah32176-bib-0024){ref-type="ref"} In summary, patients were included in this randomized, double‐blind, placebo‐controlled, parallel‐group study, between 2010 and 2013, from 49 countries, and followed for a median of 25 months. Key exclusion criteria were percutaneous coronary intervention within 15 days of screening or planned percutaneous coronary intervention within 90 days after screening, coronary artery bypass graft treatment at the index event, an estimated glomerular filtration rate of less than 30 mL/min per 1.73 m^2^ of body‐surface area, a glycated hemoglobin level of less than 5.5% or more than 11.0%, or an inability to provide written informed consent. Patients were randomized to subcutaneous injections of either lixisenatide (maximum 20 μg daily) or placebo (volume matched) in addition to locally determined standards of care. The ELIXA trial showed that lixisenatide had a neutral effect with regard to the occurrence of the primary outcome (cardiovascular death, MI, stroke, or hospitalization for unstable angina) and HF hospitalization.[23](#jah32176-bib-0023){ref-type="ref"}

Covariates and Outcomes {#jah32176-sec-0007}
-----------------------

All data pertaining to baseline variables including demographics, anthropometrics, cardiovascular risk factors, and prior medical history were obtained at the time of randomization in the study. All events were reported to a centralized and independent adjudication committee who classified events according to prespecified definitions.[24](#jah32176-bib-0024){ref-type="ref"} Data on adjudicated time‐to‐event for outcomes of all‐cause death (death), cardiovascular death (cardiovascular death), heart failure hospitalization (HF), fatal and nonfatal myocardial infarction (MI), and fatal and nonfatal stroke (stroke) were used for analyses.

BNP and NT‐proBNP sampling was carried out at baseline. Samples were collected and analyzed at a core laboratory (Covance Central Laboratory Services, Meyrin, Switzerland). The Triage BNP assay was used to analyze BNP. The intra‐assay coefficient of variation was 1.1% to 3.1%. The interassay coefficient of variation was 1.8% to 6.6%. The Immulite NT‐proBNP assay was used to analyze NT‐proBNP. The intra‐assay coefficient of variation was 2.3% to 5.4%. The interassay coefficient of variation was 4.0% to 6.4%. BNP and NT‐proBNP samples from 5925 patients (98%) were obtained.

Statistical Analyses {#jah32176-sec-0008}
--------------------

Baseline characteristics shown in Table [1](#jah32176-tbl-0001){ref-type="table-wrap"} were selected for best risk models. Patients without data on all these relevant variables, including BNP and NT‐proBNP measurements, were excluded (n=543, 9%). The distributions of baseline BNP, NT‐proBNP, and C‐reactive protein were found to be right‐skewed and were therefore log‐transformed prior to analysis. Continuous variables were included in the models unless there was clear evidence of nonlinearity.

###### 

Characteristics of All Included Patients

                                     No Cardiovascular Events (n=4626)   Cardiovascular Events (n=899)   *P* Value
  ---------------------------------- ----------------------------------- ------------------------------- -----------
  Randomized to lixisenatide         2327 (50.3%)                        449 (49.9%)                     0.84
  Age, y                             59.7±9.5                            63.3±9.7                        \<0.001
  Male (%)                           3238 (70.0%)                        627 (69.7%)                     0.88
  BMI, kg/m^2^                       30.0±5.6                            30.3±6.1                        0.24
  Race                                                                                                   \<0.001
  Asian                              648 (14.0%)                         82 (9.1%)                       
  Black                              14 (3.1%)                           47 (5.2%)                       
  Other                              385 (8.3%)                          86 (9.6%)                       
  White                              3451 (74.6%)                        684 (76.1%)                     
  Ethnicity---Hispanic               1396 (30.2%)                        250 (27.8%)                     0.16
  Region                                                                                                 \<0.001
  Africa/Near East                   215 (4.6%)                          54 (6.0%)                       
  Asia Pacific                       597 (12.9%)                         72 (8.0%)                       
  Eastern Europe                     1172 (25.3%)                        241 (26.8%)                     
  North America                      563 (12.2%)                         153 (17.0%)                     
  South and Centr. America           1551 (33.5%)                        273 (30.4%)                     
  Western Europe                     528 (11.4%)                         106 (11.8%)                     
  Systolic blood pressure, mm Hg     129±17                              131±19                          0.86
  Diastolic blood pressure, mm Hg    77±10                               77±11                           0.18
  Heart rate, bpm                    70±10                               71±11                           0.001
  Current smoker                     511 (11.0%)                         117 (13.0%)                     0.09
  Former smoker                      2113 (45.7%)                        409 (45.5%)                     0.92
  Medical history                                                                                        
  MI                                 918 (19.8%)                         340 (37.7%)                     \<0.001
  HF                                 905 (19.5%)                         330 (36.7%)                     \<0.001
  Atrial fibrillation/flutter        240 (5.2%)                          121 (13.5%)                     \<0.001
  PAD                                271 (5.9%)                          142 (15.8%)                     \<0.001
  TIA                                83 (1.8%)                           44 (4.9%)                       \<0.001
  Ventricular tachycardia            57 (1.2%)                           17 (1.9%)                       0.12
  Stroke                             201 (4.3%)                          91 (10.1%)                      \<0.001
  CABG                               309 (6.7%)                          151 (16.8%)                     \<0.001
  Implanted pacemaker                102 (2.2%)                          41 (4.6%)                       \<0.001
  Carotid disease                    87 (1.9%)                           52 (5.8%)                       \<0.001
  Hypertension                       3449 (74.6%)                        761 (84.6%)                     \<0.001
  Index event                                                                                            \<0.001
  STEMI                              2146 (46.4%)                        297 (33.0%)                     
  NSTEMI                             1702 (36.8%)                        432 (48.1%)                     
  Unstable angina pectoris           778 (16.8%)                         170 (18.9%)                     
  PCI at index event                 2943 (63.6%)                        463 (51.5%)                     \<0.001
  Insulin‐treated                    1699 (36.7%)                        460 (51.2%)                     \<0.001
  Duration of diabetes mellitus, y   8.8±7.9                             11.9±9.5                        \<0.001
  Retinopathy                        452 (9.8%)                          139 (15.5%)                     \<0.001
  Neuropathy                         714 (15.4%)                         205 (22.8%)                     \<0.001
  Asthma                             114 (2.5%)                          40 (4.4%)                       \<0.001
  COPD                               173 (3.7%)                          76 (8.5%)                       \<0.001
  HbA1c, %                           7.6±1.3                             7.9±1.3                         \<0.001
  HDL, mg/dL                         43±11                               43±11                           0.65
  LDL, mg/dL                         77±34                               83±39                           \<0.001
  eGFR, mL/min per 1.73 m^2^         77.5±21.1                           68.1±20.6                       \<0.001
  Albuminuria                                                                                            \<0.001
  Normoalbuminuria                   3558 (76.9%)                        544 (60.5%)                     
  Microalbuminuria                   829 (17.9%)                         234 (26.0%)                     
  Macroalbuminuria                   239 (5.2%)                          121 (13.5%)                     
  Hemoglobin, g/dL                   13.8±1.4                            13.5±1.5                        \<0.001
  Na, mmol/L                         140.4±2.9                           140.3±3.1                       0.75
  Albumin, g/dL                      4.1±0.3                             3.9±0.4                         \<0.001
  CRP, mg/dL                         2.0 (1.9--2.0)                      2.7 (2.4--2.9)                  \<0.001
  BNP, pg/mL                         95 (92--98)                         198 (184--213)                  \<0.001
  NT‐proBNP, pg/mL                   285 (274--295)                      703 (644--766)                  \<0.001

BMI indicates body mass index; bpm, beats per minute; BNP, B‐type natriuretic peptide; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high‐density lipoproteins; HF, heart failure; LDL, low‐density lipoproteins; MI, myocardial infarction; NSTEMI, non‐ST elevation myocardial infarction; NT‐proBNP, N‐terminal prohormone B‐type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; TIA, transient ischemic attack.
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Cox proportional hazard modeling was used to create best risk models without BNP or NT‐proBNP using forward selection with a cut‐off value of 0.05. Separate base risk models were created for the following outcomes; death, cardiovascular death, fatal or nonfatal MI, fatal or nonfatal HF hospitalization, as well as fatal or nonfatal stroke. The variables selected were ordered according to their χ^2^ value and sorted in descending order for each outcome. The predictive ability of base risk models were assessed using Harrell\'s C statistics. Selected 30‐day models were made for comparison with previous studies. Using the selected variables from the base model, comparison between the predictive ability of the base model compared to the base model with log~2~BNP/log~2~NT‐proBNP was assessed for all outcomes. Changes in C statistics, Net Reclassification Index (NRI), and Integrated Discrimination Index (IDI) were estimated to evaluate the incremental value of adding BNP or NT‐proBNP to best risk models using a set time of 2 years comparable to the average follow‐up time (*somersd* package, STATA 13. *survIDINRI* package, R 2.3.2).

Identification of baseline variables independently associated with BNP/NT‐proBNP were obtained using forward selection regression models with *P*\<0.001 as a cut‐off. The 5 variables with the highest χ^2^ value were listed along with the *r* ^2^ values.

To identify the most significant predictive threshold of BNP/NT‐proBNP values, we divided the continuous BNP/NT‐proBNP concentrations into arbitrary threshold concentrations (ie, 35, 100, 125, 200, 300...1000, 2000, 5000). Then using HF hospitalization as an outcome, a fully adjusted Cox model with forward selection identified the BNP threshold concentration that most significantly separated patients into a lower versus a higher risk group. A univariate approach was also carried out using receiver operating characteristic analysis (*SENSPEC* package, STATA 13) with binary outcome of HF hospitalization to determine the optimal cut‐off value with respect to Youden index (ie, sensitivity+specificity−1). Interaction analyses between natriuretic peptides and timing of the baseline sample in temporal relation to the index ACS event for outcome of death was also performed, as was interaction between natriuretic peptides and type of ACS index event (ST‐elevation MI \[STEMI\], Non‐ST elevation MI \[NSTEMI\], Unstable Angina Pectoris \[UAP\]).

To assess whether the relationship between baseline BNP/NT‐proBNP and hazard was linear, fully adjusted Cox spline models for each outcome with transformed BNP/NT‐proBNP were analyzed. Concentrations below 35 pg/mL (BNP) or 125 pg/mL (NT‐proBNP) were considered normal, as these concentrations are commonly referenced as diagnostic thresholds for excluding HF in patients presenting in a nonacute manner.[25](#jah32176-bib-0025){ref-type="ref"} Hence, the risk of death in patients with these levels were used as references. Both unadjusted and adjusted models were used to confirm findings. Risk modeling, including interaction analyses (history of HF and log~2~BNP/log~2~NT‐proBNP), discriminatory statistics, and Cox spline models were also analyzed in patients stratified according to medical history of HF for BNP.

All BNP/NT‐proBNP values were summarized as geometric mean±95% CI. A significance level of 0.05 was considered statistically significant.

Results {#jah32176-sec-0009}
=======

Baseline Characteristics {#jah32176-sec-0010}
------------------------

Our study included 5525 patients comprising 91% of the included patients in the ELIXA trial. The median follow‐up time was 26 months. In our population, 4626 (84%) patients did not experience any cardiovascular event confirmed by adjudication. Baseline characteristics of patients with or without a cardiovascular event are listed in Table [1](#jah32176-tbl-0001){ref-type="table-wrap"} (Baseline characteristics according BNP quartiles and as linear covariates are listed in Tables [S1](#jah32176-sup-0001){ref-type="supplementary-material"} and [S2](#jah32176-sup-0001){ref-type="supplementary-material"}). Compared with patients not experiencing a cardiovascular event, those that did were in general older and more burdened with comorbidity, and were more likely to have micro‐ or macroalbuminuria, and a lower estimated glomerular filtration rate. Blood pressure was similar in both groups. Baseline BNP and NT‐proBNP were elevated in those subsequently experiencing any cardiovascular event.

Predictive Variables {#jah32176-sec-0011}
--------------------

In separate models, BNP and NT‐proBNP were the most significant predictors for each of death from any cause, death from a cardiovascular cause, HF, and stroke among the studied variables. The natriuretic peptides were the second most significant predictors for MI (Tables [2](#jah32176-tbl-0002){ref-type="table-wrap"} and [3](#jah32176-tbl-0003){ref-type="table-wrap"}). Apart from BNP/NT‐proBNP, the 14 other variables that conferred the greatest information were the following: Prior MI, body mass index, NSTEMI (index event), heart rate (HR), glycated hemoglobin, percutaneous coronary intervention at the index event (percutaneous coronary intervention), cerebrovascular disease (prior stroke/transient ischemic attack), atrial fibrillation, prior HF, sodium concentration, macroalbuminuria, peripheral artery disease (PAD), age, and LDL concentration. Fifteen and 16 variables were independently associated with concentrations of BNP/NT‐proBNP at the α=0.001 level and accounted for 26% and 34% of patient‐level variability, respectively. The 5 strongest associated variables are listed in Tables [S3](#jah32176-sup-0001){ref-type="supplementary-material"} through [S5](#jah32176-sup-0001){ref-type="supplementary-material"}.

###### 

Predictors of Outcomes Ranked 1 to 5 According to χ^2^ Value Using Base Variables and BNP (n=5525)

  Outcome                             1^st^                           2^nd^                          3^rd^                                 4th                                                            5th
  ----------------------------------- ------------------------------- ------------------------------ ------------------------------------- -------------------------------------------------------------- ------------------------------
  Death (397 events)                  log~2~BNP (χ^2^:203, HR 1.67)   AF (χ^2^:11, HR 1.60)          NSTEMI (χ^2^:11, HR 1.41)             Na[a](#jah32176-note-0004){ref-type="fn"} (χ^2^:10, HR 1.08)   HR per 10 (χ^2^:10, HR 1.17)
  Cardiovascular death (286 events)   log~2~BNP (χ^2^:201, HR 1.82)   HbA1c (χ^2^:13, HR 1.18)       AF (χ^2^:13, HR 1.79)                 NSTEMI (χ^2^:9, HR 1.46)                                       HR per 10 (χ^2^:9, HR 1.19)
  MI (473 events)                     Prior MI (χ^2^:46, HR 1.96)     log~2~BNP (χ^2^:44, HR 1.23)   NSTEMI (χ^2^:29, HR 1.66)             Prior stroke (χ^2^:13, HR 1.69)                                PAD (χ^2^:10, HR 1.52)
  HF (221 events)                     log~2~BNP (χ^2^:135, HR 1.80)   BMI per 5 (χ^2^:34, HR 1.33)   HR per 10 (χ^2^:17, HR 1.30)          Prior HF (χ^2^:13, HR 1.82)                                    Prior MI (χ^2^:12, HR 1.67)
  Stroke (115 events)                 log~2~BNP (χ^2^:23, HR 1.35)    Prior TIA (χ^2^:13, HR 3.12)   Macroalbuminuria (χ^2^:11, HR 2.35)   Age per 10 (χ^2^:9, HR 1.36)                                   LDL per 10 (χ^2^:4, HR 1.06)

Hazard ratios reflect 1 unit changes if nothing else is stated. For log~2~BNP that translates into a doubling of the untransformed BNP concentrations. Macroalbuminuria: \>300 mg albumin excretion/24 hours. All variables are significant, *P*\<0.05. AF indicates atrial fibrillation/flutter; BNP, B‐type natriuretic peptide; HbA1c, glycated hemoglobin; HR, heart rate; LDL, low‐density lipoproteins; MI, myocardial infarction; NSTEMI, non‐ST elevation myocardial infarction at index event; PAD, peripheral artery disease; TIA, transient ischemic attack.

1 mmol/L decreases below 140 mmol/L.
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###### 

Predictors of Outcomes Ranked 1 to 5 According to χ^2^ Value Using Base Variables and NT‐proBNP (n=5525)

  Outcome                             1^st^                                 2^nd^                                3^rd^                                 4th                                                            5th
  ----------------------------------- ------------------------------------- ------------------------------------ ------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------
  Death (397 events)                  log~2~NT‐proBNP (χ^2^:215, HR 1.52)   NSTEMI (χ^2^:10, HR 1.40)            PCI (χ^2^:10, HR 0.71)                DBP[a](#jah32176-note-0006){ref-type="fn"} (χ^2^:8, HR 1.02)   Na[b](#jah32176-note-0007){ref-type="fn"} (χ^2^:8, HR 1.04)
  Cardiovascular death (286 events)   log~2~NT‐proBNP (χ^2^:226, HR 1.65)   HbA1c (χ^2^:14, HR 1.20)             NSTEMI (χ^2^:10, HR 1.47)             AF (χ^2^:9, HR 1.62)                                           Prior HF (χ^2^:8, HR 1.44)
  MI (473 events)                     Prior MI (χ^2^:49, HR 2.00)           log~2~NT‐proBNP (χ^2^:37, HR 1.17)   NSTEMI (χ^2^:29, HR 1.66)             Prior stroke (χ^2^:13, HR 1.71)                                PAD (χ^2^:9, HR 1.48)
  HF (221 events)                     log~2~NT‐proBNP (χ^2^:132, HR 1.61)   BMI per 5 (χ^2^:31, HR 1.31)         NSTEMI (χ^2^:14, HR 1.90)             Prior HF (χ^2^:14, HR 1.73)                                    Prior MI (χ^2^:12, HR 1.69)
  Stroke (115 events)                 log~2~NT‐proBNP (χ^2^:19, HR 1.25)    Prior TIA (χ^2^:13, HR 3.09)         Macroalbuminuria (χ^2^:10, HR 2.34)   Age per 10 (χ^2^:7, HR 1.32)                                   LDL per 10 (χ^2^:4, HR 1.05)

Hazard ratios reflect 1 unit changes if nothing else is stated. For log~2~NT‐proBNP that translates into a doubling of the untransformed NT‐proBNP concentrations. Macroalbuminuria: \>300 mg albumin excretion/24 hours. All variables are significant, *P*\<0.05. AF indicates atrial fibrillation/flutter; BMI, body mass index; HbA1c, glycated hemoglobin; HF, heart failure; HR, heart rate; LDL, low‐density lipoproteins; MI, myocardial infarction; NT‐proBNP, N‐terminal prohormone B‐type natriuretic peptide; NSTEMI, non‐ST elevation myocardial infarction at index event; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

1 mm Hg decreases below 70 mm Hg.

1 mmol/L decreases below 140 mmol/L.
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Enhanced Prediction With BNP and NT‐proBNP {#jah32176-sec-0012}
------------------------------------------

To estimate the predictive strength of BNP alone, C statistics were compared between base models without BNP versus BNP alone. This showed that the discriminatory ability of base models without BNP versus BNP was similar in outcomes of death (Harrell\'s C statistics: 0.77 both models \[0--30 days: 0.82 versus 0.88, *P*=0.26\]) and in cardiovascular death (Harrell\'s C statistics: 0.77 versus 0.79, *P*=0.17).

In contrast, BNP was significantly less discriminatory compared with best risk models without BNP for the outcomes of MI (Harrell\'s C statistics: 0.71 versus 0.62), HF (Harrell\'s C statistics: 0.84 versus 0.77) and stroke (Harrell\'s C statistics: 0.75 versus 0.67) (all *P*≤0.01). Similar estimates and trends were evident for NT‐proBNP.

The strength of BNP and NT‐proBNP as contributors to risk prediction translated into augmented predictive ability of risk models for all outcomes, as summarized in the increases in C statistics, NRI, and Integrated Discrimination Index (Table [4](#jah32176-tbl-0004){ref-type="table-wrap"}). Although BNP and NT‐proBNP did not increase the C statistics for the risk model for stroke, both peptides improved NRI significantly.

###### 

Discriminatory Changes in Best Risk Models With and Without BNP and NT‐proBNP

                                      C Statistics in Each Model (n=5525)                                                                                                                          
  ----------------------------------- ------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------
  Death (397 events)                                                                                                                                                                               
  BNP                                 0.77 (74--0.79)                       0.82 (0.80--0.84)[a](#jah32176-note-0009){ref-type="fn"}   30.6% (25.2--36.8)[a](#jah32176-note-0009){ref-type="fn"}   5.0% (3.5--7.2)[a](#jah32176-note-0009){ref-type="fn"}
  NT‐proBNP                                                                 0.81 (0.79--0.83)[a](#jah32176-note-0009){ref-type="fn"}   24.3% (17.4--29.3)[a](#jah32176-note-0009){ref-type="fn"}   3.3% (2.1--5.0)[a](#jah32176-note-0009){ref-type="fn"}
  Cardiovascular death (286 events)                                                                                                                                                                
  BNP                                 0.77 (0.74--0.80)                     0.83 (0.81--0.86)[a](#jah32176-note-0009){ref-type="fn"}   36.0% (27.4--41.4)[a](#jah32176-note-0009){ref-type="fn"}   5.6% (3.4--8.6)[a](#jah32176-note-0009){ref-type="fn"}
  NT‐proBNP                                                                 0.83 (0.80--0.86)[a](#jah32176-note-0009){ref-type="fn"}   30.9% (21.7--36.9)[a](#jah32176-note-0009){ref-type="fn"}   4.0% (2.4--6.3)[a](#jah32176-note-0009){ref-type="fn"}
  MI (473 events)                                                                                                                                                                                  
  BNP                                 0.71 (0.68--0.73)                     0.72 (0.70--0.75)[a](#jah32176-note-0009){ref-type="fn"}   14.3% (9.3--19.5)[a](#jah32176-note-0009){ref-type="fn"}    1.2% (0.6--2.1)[a](#jah32176-note-0009){ref-type="fn"}
  NT‐proBNP                                                                 0.72 (0.67--0.74)[a](#jah32176-note-0009){ref-type="fn"}   10.6% (5.7--16.6)[a](#jah32176-note-0009){ref-type="fn"}    0.8% (0.3--1.6)[a](#jah32176-note-0009){ref-type="fn"}
  HF (221 events)                                                                                                                                                                                  
  BNP                                 0.84 (0.81--0.86)                     0.87 (0.85--0.89)[a](#jah32176-note-0009){ref-type="fn"}   35.4% (24.7--40.6)[a](#jah32176-note-0009){ref-type="fn"}   5.0% (3.0--7.6)[a](#jah32176-note-0009){ref-type="fn"}
  NT‐proBNP                                                                 0.87 (0.84--0.89)[a](#jah32176-note-0009){ref-type="fn"}   29.9% (21.8--36.6)[a](#jah32176-note-0009){ref-type="fn"}   3.8% (2.2--5.8)[a](#jah32176-note-0009){ref-type="fn"}
  Stroke (115 events)                                                                                                                                                                              
  BNP                                 0.74 (0.70--0.79)                     0.76 (0.72--0.80)                                          19.3% (8.8--29.9)[a](#jah32176-note-0009){ref-type="fn"}    0.4% (0--1.2)
  NT‐proBNP                                                                 0.76 (0.72--0.80)                                          17.2% (6.3--28.1)[a](#jah32176-note-0009){ref-type="fn"}    0.2% (0--0.8)

NRI and IDI summarized as mean percent improvement ±95% CI. BNP indicates B‐type natriuretic peptide; HF, heart failure; IDI, Integrated Discrimination Index; MI, myocardial infarction; NRI, Net Reclassification Index; NT‐proBNP, N‐terminal prohormone B‐type natriuretic peptide.

*P*\<0.05, comparison between base model and BNP/NT‐proBNP model.
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BNP and NT‐proBNP were the most predictive variables in risk models of type of cardiovascular death; however, when added to best risk models, BNP and NT‐proBNP only significantly improved the predictive ability (Harrel\'s C statistics) in outcomes of fatal HF and sudden death; fatal HF (n=39) (Base model: 0.850, BNP: +0.085, NT‐proBNP: +0.086, both *P*\<0.001), and sudden death (n=116) (Base model: 0.773, BNP: +0.024, NT‐proBNP: +0.037, *P*=0.20 and 0.046, respectively), but not in outcome of fatal MI (n=52) (Base model: 0.827, BNP: +0.025, NT‐proBNP: +0.016, *P*=0.24 and 0.37, respectively).

In univariate analysis, a BNP concentration of 228 pg/mL best separated patients into a lower versus higher group at risk of subsequent HF (sensitivity: 0.62, specificity: 0.77, Youden index: 0.39), with a corresponding threshold for NT‐proBNP of 751 pg/mL (sensitivity: 0.67, specificity: 0.74, Youden index: 0.41). In adjusted Cox models, a BNP concentration of 500 pg/mL provided the most significant threshold by which to further identify patients at lower versus higher risk of subsequent HF (HR 3.0 \[2.1--4.1\], *P*\<0.0001), with a corresponding threshold for NT‐proBNP of 700 pg/mL (HR 2.5 \[1.7--3.5\], *P*\<0.0001).

Predictive Strength of BNP Compared to NT‐proBNP {#jah32176-sec-0013}
------------------------------------------------

There was no significant increase in C statistics when BNP was included in the best risk models compared to NT‐proBNP in outcomes of death +0.002 (*P*=0.55), cardiovascular death +0.0002 (*P*=0.97), MI +0.002 (*P*=0.50), HF +0.0001 (*P*=0.98), stroke +0.002 (*P*=0.88). The comparable estimates were confounded by a significant correlation between BNP and NT‐proBNP (Spearman\'s rho 0.86, *P*\<0.0001).

Subgroup and Sensitivity Analyses {#jah32176-sec-0014}
---------------------------------

In our population, 22% had a history of HF. As sensitivity analysis, patients were stratified according to history of HF at baseline to provide ranking and estimates of important risk factors, although there was no significant interaction with natriuretic peptides and history of HF (death; BNP, *P*=0.57. NT‐proBNP, *P*=0.21, Figure [S1](#jah32176-sup-0001){ref-type="supplementary-material"}). BNP was the strongest prognostic variable for all outcomes examined in both groups (±prior HF; Tables [S6](#jah32176-sup-0001){ref-type="supplementary-material"} through [S8](#jah32176-sup-0001){ref-type="supplementary-material"}). Sensitivity analysis was also done in the subset of patients (52%) without any prior cardiovascular disease at baseline (HF, atrial fibrillation, peripheral artery disease, transient ischemic attack/stroke, ventricular tachycardia, coronary artery bypass graft or MI apart from index event). The same trends were also evident in this subset (Tables [S9](#jah32176-sup-0001){ref-type="supplementary-material"} and [S10](#jah32176-sup-0001){ref-type="supplementary-material"}).

Analysis in the subset of patients that had information on left ventricular ejection fraction present at their index ACS was performed (n=3390). Left ventricular ejection fraction was not among the 3 most significant predictors across all outcomes when added to the variable list. The predictive ability of BNP and NT‐proBNP was comparable in this subset compared to the entire cohort (Tables [S11](#jah32176-sup-0001){ref-type="supplementary-material"} through [S13](#jah32176-sup-0001){ref-type="supplementary-material"}).

The timing of the sampling in relation to the index ACS event did not affect the risk estimates for death for BNP (*P*=0.63) or NT‐proBNP (*P*=0.46), nor did the type of ACS (BNP, *P*=0.30; NT‐proBNP, *P*=0.32).

There was no significant interaction between sex and concentrations of BNP (*P*=0.17) or NT‐proBNP (*P*=0.58) when tested in a fully adjusted model.

Discussion {#jah32176-sec-0015}
==========

Our goal was to examine the strength of BNP and NT‐proBNP in predicting a range of cardiovascular outcomes in high risk ACS patients with type 2 diabetes mellitus. We found that baseline levels of these natriuretic peptides were elevated in patients with a subsequent cardiovascular event during follow‐up compared with those not having an event. The levels of natriuretic peptides most likely reflect that all patients recently suffered a coronary event and on average had a high comorbid burden.

The significance of elevated natriuretic peptides was reiterated when BNP and NT‐proBNP were added to risk models of major cardiovascular outcomes. Ranked according to the strength of prediction, BNP and NT‐proBNP were the primary predictive variables in all outcomes examined, except MI, where they were the second most predictive variable. The predictive strength of BNP and NT‐proBNP was also evident when viewing the χ^2^ values, which were magnitudes higher than other significant variables in death, cardiovascular death and HF, moderately higher in stroke, and comparable to having had a prior MI in outcome of MI. This was also mirrored in the ability of BNP and NT‐proBNP to predict causes of death, where a significant predictive contribution of BNP and NT‐proBNP was present when added to risk models in outcome of sudden death and HF death, whereas none was found for fatal MI. The cut‐off point that most significantly divided patients into a higher versus lower risk group of subsequent HF hospitalization was 500 and 700 pg/mL for BNP and NT‐proBNP, in multivariate analysis.

Natriuretic peptides are primarily recognized as predictors of mortality and HF hospitalization, whereas our finding of a strong predictive ability of natriuretic peptide levels in outcomes of MI and stroke is less validated, especially in ACS patients. This ability could be attributed to higher levels of natriuretic peptides in patients with asymptomatic myocardial ischemia[15](#jah32176-bib-0015){ref-type="ref"}, [16](#jah32176-bib-0016){ref-type="ref"} and paroxysmal atrial fibrillation,[17](#jah32176-bib-0017){ref-type="ref"}, [18](#jah32176-bib-0018){ref-type="ref"} which could predispose to both MI and stroke.

Our risk models also identified other important predictors apart from BNP and NT‐proBNP. Risk models in other diabetic populations (TREAT \[Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin‐alfa) Therapy\]),[26](#jah32176-bib-0026){ref-type="ref"} UKPDS \[UK Prospective Diabetes Study\][27](#jah32176-bib-0027){ref-type="ref"}) have yielded results that also highlight the importance of the risk factors we identified, such as prior HF, glycated hemoglobin, age, heart rate, albuminuria, and cardiac arrhythmias.[28](#jah32176-bib-0028){ref-type="ref"}, [29](#jah32176-bib-0029){ref-type="ref"} Important differences were that these studies either used composite end points[28](#jah32176-bib-0028){ref-type="ref"} or only single outcomes[29](#jah32176-bib-0029){ref-type="ref"} when examining predictors. Furthermore, the diabetic patients on which these risk models were based were either at higher risk (TREAT: 81.1 deaths per 1000 PY) or lower risk of death (UKPDS: 18.9 deaths per 1000 PY) than in the present study (32.3 deaths per 1000 PY). Nonetheless, traditional cardiovascular risk factors combined with markers of chronic dysglycemia seem to persist as predictors of adverse cardiovascular events despite the differences in the diabetic populations studied.

When BNP or NT‐proBNP was used to predict death or cardiovascular death alone compared to using all variables available excluding these natriuretic peptides, estimates of C statistics were comparable, but the stand‐alone natriuretic peptide receiver operating characteristic area under the curve values exceeded those reported earlier in patients with HF or coronary artery disease.[19](#jah32176-bib-0019){ref-type="ref"}, [30](#jah32176-bib-0030){ref-type="ref"} Thus, a single measurement of BNP or NT‐proBNP contains the same predictive information about risk of death as all other variables listed in Table [1](#jah32176-tbl-0001){ref-type="table-wrap"}. Of note, the reverse was seen in cardiovascular morbidity (MI, HF, stroke) where best risk models outperformed a single BNP or NT‐proBNP measurement. As visually depicted in the [figure](#jah32176-fig-0001){ref-type="fig"}, differences in natriuretic peptides conferred ≈20‐fold changes in risk of death. This large risk gradient enables easier identification of patients at higher versus lower risk and reinforces the prognostic information contained in BNP and NT‐proBNP levels.

![The association of BNP and NT‐proBNP concentrations and risk of all‐cause death. The hazard of death is depicted with 95% CIs. The reference of hazard ratio=1.0 corresponds to a BNP concentration of 35 pg/mL, and a NT‐proBNP concentration of 125 pg/mL. BNP indicates B‐type natriuretic peptide; NT‐proBNP, N‐terminal prohormone BNP.](JAH3-6-e004743-g001){#jah32176-fig-0001}

The addition of either natriuretic peptide to best risk models improved the discriminatory ability significantly. This was evident in the changes in C statistics, NRI, and Integrated Discrimination Index. C statistics increased 0.01 to 0.06 depending on outcome, which was reflected in NRI increases of 10.6% to 35.4%. These changes make both BNP and NT‐proBNP valuable prognostic determinants that should be considered in future risk determination in a comparable population. Furthermore, history of HF did not influence the predictive ability of BNP or NT‐proBNP across all outcomes, including MI and stroke.

Having diabetes mellitus seems to influence levels of natriuretic peptides in both the absence and presence of cardiovascular disease,[31](#jah32176-bib-0031){ref-type="ref"}, [32](#jah32176-bib-0032){ref-type="ref"} which potentially could change the relationship between levels of natriuretic peptides and risk of cardiovascular events. Whether natriuretic peptides predict outcomes differently in ACS patients with type 2 diabetes mellitus compared to similar patients without diabetes mellitus is not known. The stand‐alone discriminatory strength of BNP and NT‐proBNP in cardiovascular death was somewhat lower (receiver operating characteristic area under the curve: BNP 0.58; NT‐proBNP 0.68) in patients with coronary artery disease from the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial (≈16% patients had diabetes mellitus). In comparison, when BNP was sampled 2 to 4 days after the infarct in STEMI patients included in the Enoxaparin Tenecteplase‐Tissue‐Type Plasminogen Activator With or Without Glycoprotein IIb/IIIa Inhibitor as Reperfusion Strategy in ST‐Segment Elevation Myocardial Infarction‐Thrombolysis In Myocardial Infarction‐23 (ENTIRE‐TIMI‐23) trial (≈13% patients had diabetes mellitus), the receiver operating characteristic area under the curve for death after 30 days was 0.81,[11](#jah32176-bib-0011){ref-type="ref"} which is comparable to our results (area under the curve~30 days~: 0.88). This could suggest that the severity of the coronary pathology influences the predictive strength of natriuretic peptides and/or the timing of the sample used for risk determination is important, as shown by Lindahl et al.[33](#jah32176-bib-0033){ref-type="ref"} Earlier studies have shown that levels of natriuretic peptides are dynamic in the subacute phase following an MI,[34](#jah32176-bib-0034){ref-type="ref"} and smaller studies suggest that patients are at higher risk of death and left ventricular remodeling if natriuretic peptides continue to be elevated after the MI, compared with those with decreasing levels.[35](#jah32176-bib-0035){ref-type="ref"}, [36](#jah32176-bib-0036){ref-type="ref"} In our study, patients were randomized within 180 days from their ACS. The timing of the baseline sample in relation to their index ACS did not affect the risk estimates of BNP or NT‐proBNP, nor did the type of index event (STEMI, NSTEMI, or UAP). This suggests that the predictive value of natriuretic peptides is retained from shortly after the event until at least 6 months after the ACS in patients with type 2 diabetes mellitus, irrespective of coronary pathology.

As the availability of BNP and NT‐proBNP analyses differs between institutions and regions, we also assessed the predictive value of BNP compared to NT‐proBNP. In the PEACE trial, BNP was only a predictor of HF, while NT‐proBNP was a predictor of cardiovascular death, HF, and stroke in coronary artery disease patients.[19](#jah32176-bib-0019){ref-type="ref"} Neither biomarker predicted MI. In the Valsartan Heart Failure Trial (Val‐Heft), NT‐proBNP proved superior to BNP in predicting a composite of morbidity and mortality and HF hospitalization in chronic HF patients; however, the incremental discriminatory value of NT‐proBNP versus BNP was small.[30](#jah32176-bib-0030){ref-type="ref"} In our study of ACS patients with type 2 diabetes mellitus, both natriuretic peptides had comparable predictive strength in all outcomes studied (death, cardiovascular death, MI, HF, and stroke), albeit NRI and Integrated Discrimination Index values increased slightly more with BNP across all outcomes.

Our results expand knowledge of earlier findings of enhanced risk prediction using natriuretic peptides in patients with a recent ACS[3](#jah32176-bib-0003){ref-type="ref"}, [10](#jah32176-bib-0010){ref-type="ref"}, [11](#jah32176-bib-0011){ref-type="ref"}, [12](#jah32176-bib-0012){ref-type="ref"} to also include patients with a recent ACS and type 2 diabetes mellitus. This prevalent population has only marginally been studied in this context.[37](#jah32176-bib-0037){ref-type="ref"}, [38](#jah32176-bib-0038){ref-type="ref"}, [39](#jah32176-bib-0039){ref-type="ref"}, [40](#jah32176-bib-0040){ref-type="ref"} The use of BNP or NT‐proBNP for risk prediction in all ACS patients, irrespective of diabetes mellitus status, is now further substantiated. Whether drugs that directly influence natriuretic peptide concentrations (eg, sacubitril[41](#jah32176-bib-0041){ref-type="ref"}) can modify the incidence of the cardiovascular outcomes examined in this study remains speculative.

Limitations {#jah32176-sec-0016}
-----------

To learn more about how diabetes mellitus per se affects the predictive ability of natriuretic peptides, a similar study design with ACS patients with and without type 2 diabetes mellitus would have been optimal. Furthermore, our average follow‐up time of ≈2 years precludes any estimates on the long‐term predictive ability of BNP and NT‐proBNP. Data on the severity of the index ACS were not obtained (eg, troponin), which as a marker of myocardial damage could have attenuated the prognostic ability of BNP/NT‐proBNP. Extrapolating from the present study to other ACS patients with type 2 diabetes mellitus should be done cautiously, as inclusion criteria may have led to selection bias compared to patients not included in this trial. Importantly, patients with estimated glomerular filtration rate \<30 mL/min per 1.73 m^2^ were excluded from this study, and renal function is shown to affect levels of natriuretic peptides.[42](#jah32176-bib-0042){ref-type="ref"}

Conclusion {#jah32176-sec-0017}
==========

In a population of patients with a recent ACS and type 2 diabetes mellitus, BNP and NT‐proBNP are important and comparable predictors of death, cardiovascular death, MI, HF, as well as stroke. Both natriuretic peptides improve the discriminatory ability significantly when added to best risk models with known predictors of adverse cardiovascular outcomes, irrespective of prior history of HF or prior cardiovascular disease.
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